SU-E-T-31: Dosimetric Evaluation of Radiation Therapy Techniques for Early Stage Glottic Squamous Cell Carcinoma (SCC): Three Dimensional Conformal Radiation Therapy (3D CRT), Step-And-Shoot Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modu

2012 ◽  
Vol 39 (6Part10) ◽  
pp. 3709-3709
Author(s):  
T De La Fuente Herman ◽  
C Matthiesen ◽  
H Singh ◽  
C Higby ◽  
H Ortega ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Early Stage ◽  
Three Dimensional ◽  
Intensity Modulated Radiation Therapy ◽  
Conformal Radiation Therapy ◽  
Intensity Modulated ◽  
Step And Shoot ◽  
3D Crt

scholarly journals Three-Dimensional Conformal Radiotherapy-Based or Intensity-Modulated Radiotherapy-Based Concurrent Chemoradiotherapy in Patients with Thoracic Esophageal Squamous Cell Carcinoma

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1529 ◽  
Author(s):  
Wei-Cheng Lin ◽  
Chia-Lun Chang ◽  
Han-Lin Hsu ◽  
Kevin Sheng-Po Yuan ◽  
Alexander T. H. Wu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Radiation Therapy ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Three Dimensional ◽  
Intensity Modulated ◽  
Clinical Stages ◽  
Group 2 ◽  
3D Crt

Background: To date, intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) and CCRT with standard fractionation three-dimensional conformal radiation therapy (3D-CRT) have not been compared. In this study, the outcomes of IMRT-based concurrent CCRT and those of 3D-CRT-based CCRT were compared in patients with thoracic esophageal squamous cell carcinoma (TESCC). Methods: We enrolled 2062 patients with TESCC who had received CCRT and categorized them into two groups on the basis of their treatment modality: Group 1 (3D-CRT-based CCRT) and Group 2 (IMRT-based CCRT). Results: Multivariate Cox regression analysis indicated that the American Joint Committee on Cancer advanced stages (≥IIIA) and 3D-CRT were significant independent predictors of poor outcomes in patients with TESCC who received definitive CCRT. Moreover, receiving IMRT-based CCRT (adjusted hazard ratio [aHR]: 0.88, 95% confidence interval [CI]: 0.78–0.98) was a significant independent prognostic factor for overall survival (p = 0.0223). In Group 2, aHRs (95% CIs) for overall mortality at early (IA–IIB) and advanced clinical stages were 0.91 (0.67–1.25, p = 0.5746) and 0.88 (0.77–0.99, p = 0.0368), respectively. Conclusion: IMRT-based CCRT resulted in higher survival rates in patients with advanced clinical stages of TESCC (i.e., IIIA–IIIC), namely, clinical T3, clinical T4, or lymph node involvement.

Sign in / Sign up

Export Citation Format

Share Document